BlackRock Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

BlackRock Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$619K	Hold	47,237	–	–	﹤0.01%	2962
2016 Q3	$685K	Buy	47,237 +824	+2%	+$11.7K	﹤0.01%	2880
2016 Q2	$556K	Buy	46,413 +11,593	+33%	+$186K	﹤0.01%	3008
2016 Q1	$649K	Buy	34,820 +809	+2%	+$13.4K	﹤0.01%	2771
2015 Q4	$731K	Buy	34,011 +73	+0.2%	+$1.54K	﹤0.01%	2805
2015 Q3	$575K	Sell	33,938 -784	-2%	-$19.5K	﹤0.01%	2971
2015 Q2	$1.3M	Buy	+34,722	New	+$1.12M	﹤0.01%	2577

Other funds holding CBMG

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Investment Management's CBMG Position: Q4 2016 in Review

BlackRock Investment Management held its Cellular Biomedicine Group, Inc. (CBMG) position steady in Q4 2016 at 47,237 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #2962.

BlackRock Investment Management first reported a position in CBMG in Q2 2015 and has held it in 7 quarters since. The position peaked at $1.3M in Q2 2015. 38 funds tracked by Wall St. Rank hold CBMG as of Q4 2016.

BlackRock Investment Management held 47,237 shares of Cellular Biomedicine Group, Inc. worth $619K as of Q4 2016.
BlackRock Investment Management left its Cellular Biomedicine Group, Inc. share count unchanged in Q4 2016.
Cellular Biomedicine Group, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2962 holding.
BlackRock Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Cellular Biomedicine Group, Inc. position peaked at $1.3M in Q2 2015.
38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.